Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Bessemer Group Inc.

Bessemer Group Inc. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 139.1% in the 3rd quarter, Holdings Channel reports. The firm owned 2,671 shares of the biopharmaceutical company’s stock after purchasing an additional 1,554 shares during the period. Bessemer Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,502,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of REGN. CoreCap Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 9.2% during the third quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 20 shares during the period. Strait & Sound Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 3.5% during the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 21 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in Regeneron Pharmaceuticals by 14.8% during the 3rd quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 21 shares during the period. Independence Bank of Kentucky grew its stake in shares of Regeneron Pharmaceuticals by 7.7% in the 3rd quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock valued at $173,000 after purchasing an additional 22 shares during the last quarter. Finally, Redwood Wealth Management Group LLC increased its holdings in shares of Regeneron Pharmaceuticals by 4.8% in the second quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 23 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

REGN has been the subject of several recent research reports. Oppenheimer reaffirmed an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Scotiabank raised their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Wells Fargo & Company lifted their target price on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada lifted their price objective on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $788.57.

Regeneron Pharmaceuticals Stock Up 2.5%

REGN stock opened at $785.51 on Monday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average price is $757.29 and its 200 day moving average price is $658.82. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a market cap of $82.56 billion, a P/E ratio of 18.90, a P/E/G ratio of 2.11 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period last year, the firm earned $12.07 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a dividend of $0.94 per share. The ex-dividend date is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.47%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.